Polycystic ovarian disease .(PCOD) is a multifactorial endocrinopathy characterized by a wide range of variable manifestations such as oligoamenorrhea, clinical and biochemical signs of hyperandrogenism and hyperinsulinemia, a tendency to obesity, and typical ultrasound features. The identification of PCOD presents a number of difficulties and requires comprehensive clinical, ultrasonographic, morphological, and biochemical data. The clinical data include menstrual cycle disorders, ache, hirsutism, obesity, and metabolic manifestations of insuline resistance. Biochemical data include hyperandrogenism, an increased luteinizing hormone (LH)/follicle stimulating hormone (FSH) ratio, and insulin resistance.
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with polycystic ovary syndrome. The treatment of PCOD with associated infertility remains a problem. The antiestrogen, clomiphene citrate (CC), is the drug of first choice. Ovulation can be induced in about 75-80% of women with PCOD treated with CC; however, the overall pregnancy rate is only 30-40%. The use of exogenous gonadotropins in PCOD patients is a more acceptable treatment for CC-resistant patients, with an overall pregnancy rate of 66%. However, this is associated with a high rate of multiple pregnancies and spontaneous abortions and a greater risk of ovarian hyperstimulation syndrome (OHSS). Purified urinary FSH, it is claimed, produces a lower incidence of OHSS. Cotreatment with gonadotropin releasing hormone analogue (GnRH-a) and human menopausal gonadotropin (hMG) did not improve fertilization and pregnancy rates but had an effect on synchronizing oocyte maturation (1) . Although cotreatment with GnRH-a and gonadotropins improved the intrafollicular microenvironment by reducing the androgen concentration, patients with polycystic ovaries (PCO) yield more immature oocytes than normal patients. An associated higher cytoplasmic immaturity in women producing ->11 oocytes could explain the lower fertilization and implantation rates of high-ovarian responder patients (2) .
Administration of growth hormone (GH), in the cotreatment of superovulation induction, was shown to increase the ovarian response to gonadotropin stimulation in women relatively resistant to conventional therapy (3, 4) . The effects of GH on ovarian physiology is believed to be mediated largely by insulin-like growth factors (IGFs). Systemic and ovarian levels may rise via GH-induced hepatic production (5). Alternatively, GH receptormediated events may act independently of IGF-I, modulating gonadotropin fiormonal action (6) .
Considerable evidence shows that IGF-I exerts a stimulatory action on granulosa aromatase activity and estradiol (E2) secretion (7-9). A defective aromatase activity has been hypothesized in the pathogenesis of PCOD (10) , and an increase in androstenedione (A) levels in follicular fluids (FF) of PCO has been demonstrated (11, 12) . In the latter study (12) , significantly higher levels of epidermal growth factor (EGF) in FF from patients with PCO compared with normally ovulating women were observed. These findings suggested that the presence of biologically inactive FSH, and/or a possible imbalance between intrafollicular IGF-I and EGF, or other growth factors, might play a role in the development of PCO (12) .
Recent observations indicated a direct stimulatory effect of GH on basal aromatase activity and steroidogenesis in cultured rat (6) and human (13) granulosa cells. Moreover, the presence of functional GH receptors in human granulosa cells, in spontaneous and stimulated cycles, has been demonstrated (14) , supporting a role for GH in enhancing FSH-stimulated E2 production. A further direct effect in vitro of GH on granulosa cell differentiation, which seems to be mediated, at least in part, by the autocrine action of IGFs, particularly IGF-II, has recently been demonstrated (8) . This has led to the hypothesis that sensitization of the granulosa cells to the IGF-II produced by the cells themselves may act through the IGF-I receptor.
IGF-II has been demonstrated to be present in human FF at high concentrations (15), three to six times higher than those of IGF-I (16), and to be produced and released by human granulosa cells in culture (8) .
IGF-It levels in FF were reduced in women with PCO in comparison with normal subjects and its concentrations were not modified by administering GH with gonadotropins (16) . IGF-II is thought to exert effects similar to IGF-I on the proliferation and differentiation of ovarian follicles (7), acting mainly through the type t IGF receptor (17) . IGF-II mRNA expression has been demonstrated in normal human granulosa cells (8, 18) and in the thecal cells of PCO follicles (19) . This suggests that the paracrine/autocrine mechanism of regulation of follicular maturation, determined by the switch of IGF-I1 gene expression from thecal cells to granulosa cells, as small antral follicles advance to dominant follicles in the normal ovary, does not appear to occur in PCO follicles, reflecting follicular arrest in the PCO syndrome (19) .
The observations that GH administration increased the sensitivity of the ovary to gonadotropin stimulation, and the possible action of the GH/IGFs axis on ovarian function, have recently led to a small number of clinical trials in which GH was given with gonadotropins for treating PCO patients in in vitro fertilization/embryo transfer (IVF/ET) programs. Based on the concepts described above, Owen eta/. (20) used GH in the management of a subgroup of suboptimal responders to combined treatment with CC and hMG, in an IVF program, who had ultrasound (US)-diagnosed PCO. The purpose of supplementation with GH was, therefore, to improve the ovarian response to gonadotropins in hypogonadotropic hypogonadal patients and in patients with PCO. In the subgroup of patients with US-diagnosed PCO they found a relevant reduction in the total dose of gonadotropins required for ovarian stimulation and a significant increase in the numbers of follicles developed and of oocytes collected, fertilized, and cleaved.
Volpe etal. (21) investigated the clinical and ovarian microenvironment response to cotreatment with hMG and GH in a group of patients with endocrine and US-diagnosed PCO, and chronic anovulation with oligoamenorrhea, who were undergoing IVF/ ET and GIFT. They found that in the PCO patients with GH-supplemented cycles, the total number of gonadotropin ampoules administered was significantly lower and the duration of the cycle was sig-nificantly shorter in comparison with the previous cycle with only gonadotropin stimulation (21). On the other hand, there was no difference in the number of follicles recruited per patient or oocytes recovered per patient or in the fertilization rate between the two types of cycle. Administration of GH together with gonadotropins to PCO patients induced a significant increase in IGF-I levels in follicular fluid and, subsequently, an increase in the IGF-I/EGF and E2/A ratios.
Homburg et af. (22) hypothesized that women with PCOD have a disturbance of GH kinetics. They wished to develop the observation that obese PCO patients, and some of normal weights, had lower than normal circulating levels of GH, a reduced pituitary reserve of GH associated with insulin resistance, hyperinsulinemia, and a reduction of the IGF binding protein-1 (IGFBP-1) concentration. Moreover, it was considered that treatment with GnRHa depletes pituitary reserves of GH. On the basis of these previous investigations, their studies aimed to determine whether the distQrbance in normal GH kinetics in 30 women with PCOD may be corrected by combined GnRHa with hMG and additive GH treatment and whether this regimen would alter the ovarian response to stimulation. There were no significant differences in the number of ampoules, duration of treatment, and daily effective dose of hMG required to achieve ovulation, serum E2 concentrations, number of follicles induced, or ovulation and pregnancy rates except for a GH-induced increase in serum insulin and IGF-I levels.
Several growth factors have been demonstrated to play important roles in the regulation of ovarian follicle maturation (7, 23). IGFs are thought to be capable of amplifying the response of ovarian cells to gonadotropins, exerting a stimulatory action on granulosa cell replication and a modulation of steroidogenesis (7). IGF-I can improve E2 secretion by increasing aromatase activity (9) and induce a better ovarian response to gonadotropins (7). Recently, IGF-II has been shown to be active in stimulating E2 production by human granulosa cells in vitro, although its effect was slightly lower than that obtained with comparable doses of IGH-I (8).
The reduction of intrafollicular concentrations of IGFs may be involved in the alteration of follicular maturation observed in PCO. For example, existing evidence indicated an important role of IGFs in follicular maturation and in the development of a dominant follicle and of a relationship between oocyte maturity and IGF-I levels in FF (24). GH administration, by increasing IGF-I levels in FF, can correct IGF imbalance and overcome the defect in granulosa cell production of IGF-II in PCO patients, thus improving ovarian follicular maturation. This effect can also be achieved in ovarian stimulated non-lVF cycles.
For the future, we would recommend further elucidation of the paracrine/autocrine mechanisms of regulation of follicle and oocyte maturation by studying more closely the follicular microenvironmerit in the polycystic ovary. From a clinical point of view, more and wider randomized, double-blind, placebo-controlled trials are required to evaluate better the clinical utility and the cost-effectiveness ratio of GH supplementatio n to ovarian stimulation with gonadotropins in the treatment of infertile PCO patients.
